irinotecan,leucovorin,oxaliplatin,nab-paclitaxel,gemcitabine
Ipsen
[]
 nalirifox vs nab-paclitaxel + gemcitabine in 1l #pdac
@ asco-gi 2023 napoli-3 phs-iii, 770 pts mos 11.2 vs 9.2 mo mpfs 7.4 vs 5.6 mo orr 41 vs 36% more gi tox for nalirifox 50% subs. therapies meaningful benefit for the triplet 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine